Tango Therapeutics (TNGX) Soars 52% on Buy Reco

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 Stocks Investors Are Watching Closely This Week.

Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry of positive developments, including a “buy” recommendation for its stock and the start of a series of clinical trials for its pancreatic cancer treatment candidate vopimetostat..

In a market report during the week, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for Tango Therapeutics Inc. (NASDAQ:TNGX), following improvements in its earnings performance last year, having narrowed its net losses by 22 percent to $101.59 million from $130.3 million in 2024.

medicine

Photo by Pietro Jeng on Pexels

Total revenues, on the other hand, jumped by 48.3 percent to $62.38 million from $42.07 million year-on-year.

However, net loss in the fourth quarter widened by 26 percent to $38.7 million from $30.76 million, having earned no revenues during the period, versus a $5.4 million revenue in the same period a year earlier.

For this year, Tango Therapeutics Inc. (NASDAQ:TNGX) is targeting to kick off a number of clinical trials to test its drug candidate vopimetostat in combination with multiple inhibitors for the treatment of pancreatic cancer.

It recently clinched a partnership with Erasca to jointly study the combination of vopimetostat with ERAS-0015 in treating pancreatic cancer.

While we acknowledge the risk and potential of TNGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.